HS
SLDB icon

HighVista Strategies’s Solid Biosciences SLDB Stock Holding History

HighVista Strategies’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,104
Closed -$506K – 139
2021
Q1 		$506K Buy
+6,104
New +$675K 0.38% 70

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

HighVista Strategies's SLDB Position: Q2 2021 in Review

HighVista Strategies sold out of Solid Biosciences (SLDB) in Q2 2021, closing a stake of 6,104 shares — an estimated $506K sold.

HighVista Strategies first reported a position in SLDB in Q1 2021 and held it in 1 quarter. The position peaked at $506K in Q1 2021. 92 funds tracked by Wall St. Rank hold SLDB as of Q2 2021.

  • HighVista Strategies reported no remaining Solid Biosciences position as of Q2 2021 after selling out during the quarter.
  • HighVista Strategies sold 6,104 Solid Biosciences shares in Q2 2021, an estimated $506K.
  • HighVista Strategies first reported a position in Solid Biosciences in Q1 2021 and held it in 1 quarter.
  • HighVista Strategies's Solid Biosciences position peaked at $506K in Q1 2021.
  • 92 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2021.

Based on HighVista Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.